Junbing He

Jieyang People's Hospital

H指数:15

被引数:513

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HA-modified lipid nanoparticles delivering ASO-Hotair attenuate macrophage-driven inflammation in sepsis-associated acute lung injury

HA修饰的脂质纳米颗粒递送ASO-Hotair减轻脓毒症相关急性肺损伤中的巨噬细胞驱动的炎症

Journal of Nanobiotechnology

IF12.6

2026-10-140

OAAI

Association between glycemic variability and the risk of acute kidney injury in patients with traumatic brain injury: a retrospective cohort study with independent cohort analysis

创伤性脑损伤患者中血糖变异性与急性肾损伤风险的相关性：一项回顾性队列研究及独立队列分析

Frontiers in Neurology

IF2.8

2026-04-140

OAAI

Tetraspanin-Mediated ADAM10 Regulation in Sepsis and Potential Therapeutic Implications

四跨膜蛋白介导的ADAM10调控在败血症中的作用及潜在的治疗意义

FRONTIERS IN BIOSCIENCE-LANDMARK

IF3.1

2025-09-250

OAAI

A pyrene-based red-emissive AIEE fluorophore based on ICT and ESIPT effects for bioimaging

基于ICT和ESIPT效应的吡咯基红光发射AIEE荧光探针，用于生物成像

Dyes and Pigments

IF4.2

2025-08-080

PRE

Photodynamic therapy for oral candidiasis in human clinical trials: an evidence-based analysis

人类临床试验中口腔念珠菌病的光动力疗法：一项基于证据的分析

Photodiagnosis and Photodynamic Therapy

IF2.6

2025-07-160

Mechanistic Insights into HOTAIR-Driven ADAM17/NF-Κb Activation and Endothelial Dysfunction in LPS-Challenged HUVECs

HOTAIR驱动的ADAM17/NF-κb激活及内皮功能障碍在LPS刺激的人脐静脉内皮细胞中的机制研究

IMMUNOLOGICAL INVESTIGATIONS

IF2.4

2025-05-140

PRE

RECK as a Potential Crucial Molecule for the Targeted Treatment of Sepsis

inflammation research

IF4.1

2025-02-010

X-Ray-Triggered CA IX Inhibition Nanoplatform Promotes Intratumoral Acidosis-Induced Cancer Ferroptosis

X射线触发CA IX抑制纳米平台促进肿瘤内酸中毒诱导的癌症铁死亡

ADVANCED FUNCTIONAL MATERIALS

IF19

2024-11-200

PRE

Combination of rituximab and low-dose glucocorticoids for idiopathic refractory nephrotic syndrome with MCD/FSGS: a single-center prospective cohort study

RENAL FAILURE

IF3

2024-11-151

OAAI

Enamel matrix derivative in the treatment of tooth replantation: from a biological basis to clinical application

ANNALS OF MEDICINE

IF4.3

2024-11-090

OAAI

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis

利妥昔单抗治疗系统性红斑狼疮及狼疮性肾炎的研究进展

FRONTIERS IN MEDICINE

IF3

2024-10-041

OAAI

Oxymatrine attenuates sepsis-induced inflammation and organ injury via inhibition of HMGB1/RAGE/NF-κB signaling pathway

氧化苦参碱通过抑制HMGB1/RAGE/nf-κb信号通路减轻脓毒症炎症和器官损伤

DRUG DEVELOPMENT RESEARCH

IF4.2

2024-06-063

PRE

MiR-145 Alleviates Sepsis-Induced Inflammatory Responses and Organ Injury by Targeting ADAM17

FRONTIERS IN BIOSCIENCE-LANDMARK

IF3.1

2024-01-236

Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathy

RENAL FAILURE

IF3

2023-09-191

OAAI

The -172 A-to-G variation in ADAM17 gene promoter region affects EGR1/ADAM17 pathway and confers susceptibility to septic mortality with sepsis-3.0 criteria (vol 102, 108385, 2022)

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2023-06-010

OAAI

Genetic Arg-304-His substitution in GRK5 protects against sepsis progression by alleviating NF-?B-mediated inflammation

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2023-02-013

PRE

A comparative evaluation of lasers and photodynamic therapy in the nonsurgical treatment of peri-implant diseases: A Bayesian network meta-analysis

PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY

IF2.6

2022-12-014

OAAI

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis

RENAL FAILURE

IF3

2022-08-057

OAAI

The-172 A-to-G variation in ADAM17 gene promoter region affects EGR1/ADAM17 pathway and confers susceptibility to septic mortality with sepsis-3.0 criteria

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2022-01-017

OAAI

Investigation of Association of Complement 5 Genetic Polymorphisms with Sepsis and Sepsis-Induced Inflammatory Responses

inflammation research

IF4.1

2021-12-015

Junbing He

个人简介

教育背景

工作经历

荣誉奖项

研究方向